Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Smith, Robert A ^a   Raugi, Dana N ^a   Pan, Charlotte ^a   Coyne, Matthew ^a   Hernandez, Alexandra ^a   Church, Brad ^a   Parker, Kara ^a   Mullins, James I ^a   Sow, Papa Salif ^b   Gottlieb, Geoffrey S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Centre Hospitalier Universitaire Dakar   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PHENOTYPE; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MUTATION; PYRROLIDINONES; QUINOLONES; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84866521761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045372     Document Type: Article

References (26)

1. de Silva TI, Cotten M, Rowland-Jones SL, (2008) HIV-2: The forgotten AIDS virus. Trends Microbiol 16: 588-595.
2. Jaffar S, Grant AD, Whitworth J, Smith PG, Whittle H, (2004) The natural history of HIV-1 and HIV-2 infections in adults in Africa: A literature review. Bull World Health Organ 82: 462-469.
3. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, et al. (2002) Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 185: 905-914.
4. Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, et al. (2009) Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resource-limited West Africa. Clin Infect Dis 48: 476-483.
5. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS, (2009) Antiretroviral drug resistance in HIV-2: Three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 199: 1323-1326.
6. Menendez-Arias L, Tozser J, (2008) HIV-1 protease inhibitors: Effects on HIV-2 replication and resistance. Trends Pharmacol Sci 29: 42-49.
7. Camacho RJ, (2012) Special aspects of the treatment of HIV-2-infected patients. Intervirology 55: 179-183.
8. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, et al. (2008) In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 52: 1545-1548.
9. Ntemgwa ML, d'Aquin Toni T, Brenner BG, Camacho RJ, Wainberg MA, (2009) Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 53: 3611-3619.
10. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, et al. (2008) HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 62: 914-920.
11. Smith RA, Raugi DN, Kiviat NB, Hawes SE, Mullins JI, et al. (2011) Phenotypic susceptibility of HIV-2 to raltegravir: Integrase mutations Q148R and N155H confer raltegravir resistance. AIDS 25: 2235-2241.
12. Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, et al. (2010) In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 24: 2753-2755.
13. Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, et al. (2011) Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother 55: 1293-1295.
14. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, et al. (2008) Raltegravir treatment response in an HIV-2 infected patient: A case report. AIDS 22: 1091-1092.
15. Roquebert B, Blum L, Collin G, Damond F, Peytavin G, et al. (2008) Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 22: 2045-2046.
16. Salgado M, Toro C, Simon A, Garrido C, Blanco F, et al. (2009) Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 46: 173-175.
17. Trevino A, de Mendoza C, Caballero E, Rodriguez C, Parra P, et al. (2011) Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother 66: 1484-1488.
18. Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, et al. (2009) Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses 25: 843-847.
19. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW, (2011) HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203: 1204-1214.
20. Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, et al. (2011) G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology 8: 68.
21. Gottlieb GS, Smith RA, Dia Badiane NM, Ba S, Hawes SE, et al. (2011) HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS One 6: e22204.
22. Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, et al. (2010) Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 7: 98.
23. Piralla A, Paolucci S, Gulminetti R, Comolli G, Baldanti F, (2011) HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients. Virol J 8: 149.
24. Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, et al. (2011) Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group. Clin Infect Dis 52: 1257-1266.
25. Peterson I, Togun O, de Silva T, Oko F, Rowland-Jones S, et al. (2011) Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. AIDS 25: 2167-2175.
26. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, et al. (2009) Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol 47: 2200-2208.